Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:09 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Using Less Neurotoxic Drugs in Patients With HAND (MARAND-X)
NCT03163277 · Giovanni Di Perri · PHASE4 · terminated · last registry update 2020-11-06 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sloww accrual and COVID-19 related problems (impossible to perform LPs)” | – | Registry record, Giovanni Di Perri |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CYP3A4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-08-13Results posted on the registry: Emory University, Genvoya (NCT03976752)
- 2021-07-09Also stopped (withdrawn): Stanford University, Darunavir/Cobicistat + Dolutegravir (NCT02499978)
- 2021-05-24Results posted on the registry: Gilead Sciences, E/C/F/TAF + E/C/F/TAF (Low Dose) (NCT01854775)
- 2021-02-11Results posted on the registry: University of Colorado, Denver, TDF with a boosted protease inhibitor + TAF with a boosted protease inhibitor (NCT03126370)
- 2021-01-14Also stopped (withdrawn): Azienda Ospedaliero-Universitaria di Parma, Oxytocin + Standard of Care (NCT04386447)
- 2020-12-04Phase 3 first posted: Chelsea and Westminster NHS Foundation Trust, Biktarvy + Symtuza (NCT04653194)
- 2020-08-27Results posted on the registry: Gilead Sciences, B/F/TAF + NRTIs (NCT03631732)
- 2020-07-17Phase 3 first posted: University of Rome Tor Vergata, liposomal lactoferrin + SOC therapy (NCT04475120)
- 2020-07-07Also stopped (terminated): Janssen Pharmaceutica N.V., Belgium, Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC + Darunavir (NCT04236453)
- 2020-03-18Also stopped (withdrawn): Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic, Elvitegravir, Cobicistat, TAF, FTC + Efavirenz, TDF, and 3TC (NCT03405194)
- 2020-02-05Phase 3 first posted: Shanghai Public Health Clinical Center, Darunavir and Cobicistat (NCT04252274)
- 2020-01-07Results posted on the registry: Janssen Scientific Affairs, LLC, DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC (NCT03227861)
- 2019-12-05Results posted on the registry: Gilead Sciences, B/F/TAF (NCT03405935)
- 2019-11-26Results posted on the registry: Medicines for Malaria Venture, Single oral dose of 800 mg OZ439 + Single oral dose of 400 mg OZ439 (NCT04069221)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision